Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Several technologies for hemoglobinopathies are being transferred to commercial partners
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Subscribe To Our Newsletter & Stay Updated
